Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 7, 2014; 20(33): 11641-11649
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11641
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11641
Table 1 Classifications and context cross-resistance profiles of antiviral drugs in chronic hepatitis B[8]
| Classification | Amino acid substitution in the rt domain | LAM | LdT | ETV | ADV | TDF |
| Wild-type | S | S | S | S | S | |
| LAM + LdT resistance | M204I/V | R | R | I | S | S |
| ADV resistance | N236T | S | S | S | R | I |
| LAM + LdT + ADV (multi-drugs) resistance | A181T/V | R | R | S | R | I |
| ADV + TDF resistance | A181T/V + N236T | R | R | S | R | R |
| ETV resistance | L180M + M204I/V ± I169 ± T184 ± S202 ± M250 | R | R | R | S | S |
| TDF resistance | A194T | R | S | S | NA | R |
- Citation: Bang KB, Kim HJ. Management of antiviral drug resistance in chronic hepatitis B. World J Gastroenterol 2014; 20(33): 11641-11649
- URL: https://www.wjgnet.com/1007-9327/full/v20/i33/11641.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i33.11641